Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment Foresee Pharmaceuticals announces remarkable results from their Phase 3 Casppian study, showcasing impressive LH suppression in children with Central Precocious Puberty, with a six-month dosing schedule.

Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #leuprolide_mesylate #Central_Precocious_Puberty

Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment Foresee Pharmaceuticals has completed the enrollment for its Phase 3 Casppian trial, examining leuprolide mesylate's safety and efficacy in treating Central Precocious Puberty.

Foresee Pharmaceuticals Completes Enrollment in Phase 3 Trial for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #Casppian_trial #leuprolide_mesylate